ArticleArtificial organs2026
Baseline Ventricular-Arterial Coupling Modifies Left Atrial Pressure Response to Venoarterial Extracorporeal Membrane Oxygenation In Vitro.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) increases systemic afterload, potentially elevating mean left atrial pressure (mLAP). How baseline ventricular-arterial coupling modifies this effect remains unclear. Our aim was to determine how baseline cardiac power output (CPO) and systemic vascular resistance (SVR) modify the mLAP response to VA-ECMO, with or without valvular regurgitation.
methodsUsing a biventricular mock circulatory loop with peripheral VA-ECMO cannulation, we simulated 12 cardiogenic shock states. Measurements were obtained at baseline and at VA- ECMO pump speeds of 2000-4000 RPM. Results were stratified by baseline SVR (< 20 vs. ≥ 20 Wood units), CPO (< 0.20 vs. ≥ 0.20 W) and valve competence. Severe aortic and mitral regurgitation were tested independently as additional conditions.
resultsWith competent valves, mLAP decreased from 27.0 ± 0.2 mmHg at baseline to 19.0 ± 0.6 mmHg at 3000 RPM, then increased to 22.0 ± 0.9 mmHg at 4000 RPM. High baseline SVR produced greater mLAP reduction at 3000 RPM (15.0 ± 0.6 vs. 20.0 ± 0.7 mmHg, p < 0.001) but steeper rebound at 4000 RPM (26.0 ± 1.1 vs. 20.0 ± 0.9 mmHg, p < 0.001) compared to low SVR. Higher baseline CPO (≥ 0.20 W) maintained lower mLAP at higher speeds (16.0 ± 0.6 vs. 21.0 ± 0.7 mmHg at 3500 RPM; p < 0.001). Aortic regurgitation (AR) elevated mLAP above baseline (36.0 ± 1.5 vs. 22.0 ± 0.9 mmHg at 4000 RPM; p < 0.001), amplified by high SVR (47.0 ± 1.1 vs. 29.0 ± 0.8 mmHg at 4000 RPM). Mitral regurgitation elevated mLAP above baseline at higher pump speeds (32.0 ± 1.4 vs. 22.0 ± 0.9 mmHg at 4000 RPM; p < 0.001).
conclusionsBaseline ventricular-arterial coupling modifies mLAP response to VA-ECMO. Low CPO with high SVR, particularly with AR, narrows the safe pump speed window and may require early left ventricular unloading, inotropic support, or vascular resistance optimization. These findings support phenotype-guided VA-ECMO titration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.